Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab

Joaquín Hinojosa Del Val; Manuel Barreiro-de Acosta

doi:10.1016/j.gastrohep.2019.08.007

Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab

Gastroenterol Hepatol. 2019 Dec;42(10):650-656. doi: 10.1016/j.gastrohep.2019.08.007. Epub 2019 Oct 18.

[Article in English, Spanish]

Authors

Joaquín Hinojosa Del Val¹, Manuel Barreiro-de Acosta²

Affiliations

¹ Unidad de EII, Hospital de Manises, Universidad Católica de Valencia, Valencia, España. Electronic address: jhinojosad@gmail.com.
² Unidad de EII, Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, España.

PMID: 31635855
DOI: 10.1016/j.gastrohep.2019.08.007

Abstract

Vedolizumab is an anti-integrin monoclonal antibody indicated for the treatment of patients with moderately to severely active Crohn's disease and ulcerative colitis who have failed conventional or anti-TNF therapies. The objective of this article is to answer a series of very practical questions regarding the management of both diseases with vedolizumab, based on data from published literature, as well as on the experience acquired by the authors in clinical practice in recent years.

Keywords: Clinical practice; Colitis ulcerosa; Crohn's disease; Enfermedad de Crohn; Management; Manejo; Práctica clínica; Ulcerative colitis; Vedolizumab.

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Colitis, Ulcerative / drug therapy*
Crohn Disease / drug therapy*
Gastrointestinal Agents / therapeutic use*
Humans
Practice Guidelines as Topic
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Gastrointestinal Agents
vedolizumab